MorphoSys AG
COMBINATION OF ANTI CD19 ANTIBODY WITH A BCL-2 INHIBITOR AND USES THEREOF
Last updated:
Abstract:
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a BCL-2 inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Status:
Application
Type:
Utility
Filling date:
27 Oct 2017
Issue date:
8 Aug 2019